BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

628 related articles for article (PubMed ID: 14614001)

  • 1. Consistent antibody response against ganglioside GD2 induced in patients with melanoma by a GD2 lactone-keyhole limpet hemocyanin conjugate vaccine plus immunological adjuvant QS-21.
    Ragupathi G; Livingston PO; Hood C; Gathuru J; Krown SE; Chapman PB; Wolchok JD; Williams LJ; Oldfield RC; Hwu WJ
    Clin Cancer Res; 2003 Nov; 9(14):5214-20. PubMed ID: 14614001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Induction of antibodies against GD3 ganglioside in melanoma patients by vaccination with GD3-lactone-KLH conjugate plus immunological adjuvant QS-21.
    Ragupathi G; Meyers M; Adluri S; Howard L; Musselli C; Livingston PO
    Int J Cancer; 2000 Mar; 85(5):659-66. PubMed ID: 10699946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. GM2-KLH conjugate vaccine: increased immunogenicity in melanoma patients after administration with immunological adjuvant QS-21.
    Helling F; Zhang S; Shang A; Adluri S; Calves M; Koganty R; Longenecker BM; Yao TJ; Oettgen HF; Livingston PO
    Cancer Res; 1995 Jul; 55(13):2783-8. PubMed ID: 7796403
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ganglioside vaccines with emphasis on GM2.
    Livingston P
    Semin Oncol; 1998 Dec; 25(6):636-45. PubMed ID: 9865678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pilot study of a heptavalent vaccine-keyhole limpet hemocyanin conjugate plus QS21 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer.
    Sabbatini PJ; Ragupathi G; Hood C; Aghajanian CA; Juretzka M; Iasonos A; Hensley ML; Spassova MK; Ouerfelli O; Spriggs DR; Tew WP; Konner J; Clausen H; Abu Rustum N; Dansihefsky SJ; Livingston PO
    Clin Cancer Res; 2007 Jul; 13(14):4170-7. PubMed ID: 17634545
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunogenicity of a fucosyl-GM1-keyhole limpet hemocyanin conjugate vaccine in patients with small cell lung cancer.
    Dickler MN; Ragupathi G; Liu NX; Musselli C; Martino DJ; Miller VA; Kris MG; Brezicka FT; Livingston PO; Grant SC
    Clin Cancer Res; 1999 Oct; 5(10):2773-9. PubMed ID: 10537341
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of antibodies against GM2 ganglioside by immunizing melanoma patients using GM2-keyhole limpet hemocyanin + QS21 vaccine: a dose-response study.
    Chapman PB; Morrissey DM; Panageas KS; Hamilton WB; Zhan C; Destro AN; Williams L; Israel RJ; Livingston PO
    Clin Cancer Res; 2000 Mar; 6(3):874-9. PubMed ID: 10741710
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Approaches to augmenting the immunogenicity of melanoma gangliosides: from whole melanoma cells to ganglioside-KLH conjugate vaccines.
    Livingston PO
    Immunol Rev; 1995 Jun; 145():147-66. PubMed ID: 7590824
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Vaccination with a bivalent G(M2) and G(D2) ganglioside conjugate vaccine: a trial comparing doses of G(D2)-keyhole limpet hemocyanin.
    Chapman PB; Morrisey D; Panageas KS; Williams L; Lewis JJ; Israel RJ; Hamilton WB; Livingston PO
    Clin Cancer Res; 2000 Dec; 6(12):4658-62. PubMed ID: 11156217
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Vaccination of high-risk breast cancer patients with mucin-1 (MUC1) keyhole limpet hemocyanin conjugate plus QS-21.
    Gilewski T; Adluri S; Ragupathi G; Zhang S; Yao TJ; Panageas K; Moynahan M; Houghton A; Norton L; Livingston PO
    Clin Cancer Res; 2000 May; 6(5):1693-701. PubMed ID: 10815887
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential immunization of melanoma patients with GD3 ganglioside vaccine and anti-idiotypic monoclonal antibody that mimics GD3 ganglioside.
    Chapman PB; Wu D; Ragupathi G; Lu S; Williams L; Hwu WJ; Johnson D; Livingston PO
    Clin Cancer Res; 2004 Jul; 10(14):4717-23. PubMed ID: 15269144
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibodies against GD2 ganglioside can eradicate syngeneic cancer micrometastases.
    Zhang H; Zhang S; Cheung NK; Ragupathi G; Livingston PO
    Cancer Res; 1998 Jul; 58(13):2844-9. PubMed ID: 9661900
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1-KLH and GD3-KLH conjugates.
    Kim SK; Ragupathi G; Cappello S; Kagan E; Livingston PO
    Vaccine; 2000 Oct; 19(4-5):530-7. PubMed ID: 11027818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. GD3 vaccines for melanoma: superior immunogenicity of keyhole limpet hemocyanin conjugate vaccines.
    Helling F; Shang A; Calves M; Zhang S; Ren S; Yu RK; Oettgen HF; Livingston PO
    Cancer Res; 1994 Jan; 54(1):197-203. PubMed ID: 8261439
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of patients with small-cell lung cancer with synthetic fucosyl GM-1 conjugated to keyhole limpet hemocyanin.
    Krug LM; Ragupathi G; Hood C; Kris MG; Miller VA; Allen JR; Keding SJ; Danishefsky SJ; Gomez J; Tyson L; Pizzo B; Baez V; Livingston PO
    Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6094-100. PubMed ID: 15447995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vaccination of small cell lung cancer patients with polysialic acid or N-propionylated polysialic acid conjugated to keyhole limpet hemocyanin.
    Krug LM; Ragupathi G; Ng KK; Hood C; Jennings HJ; Guo Z; Kris MG; Miller V; Pizzo B; Tyson L; Baez V; Livingston PO
    Clin Cancer Res; 2004 Feb; 10(3):916-23. PubMed ID: 14871967
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Serological response patterns of melanoma patients immunized with a GM2 ganglioside conjugate vaccine.
    Kitamura K; Livingston PO; Fortunato SR; Stockert E; Helling F; Ritter G; Oettgen HF; Old LJ
    Proc Natl Acad Sci U S A; 1995 Mar; 92(7):2805-9. PubMed ID: 7708728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immunization of melanoma patients with BEC2-keyhole limpet hemocyanin plus BCG intradermally followed by intravenous booster immunizations with BEC2 to induce anti-GD3 ganglioside antibodies.
    Yao TJ; Meyers M; Livingston PO; Houghton AN; Chapman PB
    Clin Cancer Res; 1999 Jan; 5(1):77-81. PubMed ID: 9918205
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A preclinical study comparing approaches for augmenting the immunogenicity of a heptavalent KLH-conjugate vaccine against epithelial cancers.
    Ragupathi G; Koide F; Sathyan N; Kagan E; Spassova M; Bornmann W; Gregor P; Reis CA; Clausen H; Danishefsky SJ; Livingston PO
    Cancer Immunol Immunother; 2003 Oct; 52(10):608-16. PubMed ID: 12811527
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor cell reactivity mediated by IgM antibodies in sera from melanoma patients vaccinated with GM2 ganglioside covalently linked to KLH is increased by IgG antibodies.
    Livingston P; Zhang S; Adluri S; Yao TJ; Graeber L; Ragupathi G; Helling F; Fleisher M
    Cancer Immunol Immunother; 1997 Jan; 43(6):324-30. PubMed ID: 9067403
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.